PMID- 37895967 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231030 IS - 1424-8247 (Print) IS - 1424-8247 (Electronic) IS - 1424-8247 (Linking) VI - 16 IP - 10 DP - 2023 Oct 20 TI - Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study. LID - 10.3390/ph16101496 [doi] LID - 1496 AB - INTRODUCTION: Up to 73% of individuals with autism spectrum disorder (ASD) and intellectual disability (ID) currently have prescriptions for psychotropic drugs. This is explained by a higher prevalence of medical and psychiatric chronic comorbidities, which favors polypharmacy, increasing the probability of the appearance of adverse events (AEs). These could be a preventable cause of harm to patients with ASD and an unnecessary waste of healthcare resources. OBJECTIVE: To study the impact of pharmacogenetic markers on the prevention of AE appearance in a population with ASD and ID. METHODS: This is a cross-sectional, observational study (n = 118, 72 participants completed all information) in the ASD population. Sociodemographic and pharmacological data were gathered. The Udvalg for Kliniske Undersogelser Scale (UKU Scale) was used to identify AEs related to the use of psychotropic medication. Polymorphisms of DOP2, ABCB1, and COMT were genotyped and correlated with the AE to find candidate genes. Furthermore, a review of all medications assessed in a clinical trial for adults with autism was performed to enrich the search for potential pharmacogenetic markers, keeping in mind the usual medications. RESULTS: The majority of the study population were men (75%) with multiple comorbidities and polypharmacy, the most frequently prescribed drugs were antipsychotics (69%); 21% of the participants had four or more AEs related to psychotropic drugs. The most common were "Neurological" and" Psychiatric" (both 41%). Statistical analysis results suggested a significant correlation between the neurological symptoms and the DOP2 genotype, given that they are not equally distributed among its allelic variants. The final review considered 19 manuscripts of medications for adults with ASD, and the confirmed genetic markers for those medications were consulted in databases. CONCLUSION: A possible correlation between neurologic AEs and polymorphisms of DOP2 was observed; therefore, studying this gene could contribute to the safety of this population's prescriptions. The following studies are underway to maximize statistical power and have a better representation of the population. FAU - de Miguel, Laura AU - de Miguel L AD - Pharmacogenetic Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), General University Hospital of Alicante, c/Pintor Baeza, 12, 03010 Alicante, Spain. AD - Clinical Pharmacology, Toxicology and Chemical Safety Unit, Institute of Bioengineering, Miguel Hernandez University, Avda. de la Universidad s/n, 03202 Elche, Spain. FAU - Ballester, Pura AU - Ballester P AUID- ORCID: 0000-0002-7345-448X AD - Faculty of Pharmacy and Nutrition, Campus de los Jeronimos, Universidad Catolica San Antonio de Murcia (UCAM), Guadalupe, 30107 Murcia, Spain. FAU - Egoavil, Cecilia AU - Egoavil C AUID- ORCID: 0000-0003-0166-4901 AD - Pharmacogenetic Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), General University Hospital of Alicante, c/Pintor Baeza, 12, 03010 Alicante, Spain. AD - Clinical Pharmacology Unit, Dr. Balmis General University Hospital, 03010 Alicante, Spain. FAU - Sanchez-Ocana, Maria Luisa AU - Sanchez-Ocana ML AD - Faculty of Pharmacy and Nutrition, Campus de los Jeronimos, Universidad Catolica San Antonio de Murcia (UCAM), Guadalupe, 30107 Murcia, Spain. FAU - Garcia-Munoz, Ana Maria AU - Garcia-Munoz AM AUID- ORCID: 0000-0002-1021-5385 AD - Faculty of Pharmacy and Nutrition, Campus de los Jeronimos, Universidad Catolica San Antonio de Murcia (UCAM), Guadalupe, 30107 Murcia, Spain. FAU - Cerda, Begona AU - Cerda B AUID- ORCID: 0000-0003-0385-1145 AD - Faculty of Pharmacy and Nutrition, Campus de los Jeronimos, Universidad Catolica San Antonio de Murcia (UCAM), Guadalupe, 30107 Murcia, Spain. FAU - Zafrilla, Pilar AU - Zafrilla P AUID- ORCID: 0000-0002-1463-7120 AD - Faculty of Pharmacy and Nutrition, Campus de los Jeronimos, Universidad Catolica San Antonio de Murcia (UCAM), Guadalupe, 30107 Murcia, Spain. FAU - Ramos, Enrique AU - Ramos E AD - Clinical Pharmacology, Toxicology and Chemical Safety Unit, Institute of Bioengineering, Miguel Hernandez University, Avda. de la Universidad s/n, 03202 Elche, Spain. FAU - Peiro, Ana M AU - Peiro AM AUID- ORCID: 0000-0002-2385-3749 AD - Pharmacogenetic Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), General University Hospital of Alicante, c/Pintor Baeza, 12, 03010 Alicante, Spain. AD - Clinical Pharmacology, Toxicology and Chemical Safety Unit, Institute of Bioengineering, Miguel Hernandez University, Avda. de la Universidad s/n, 03202 Elche, Spain. AD - Clinical Pharmacology Unit, Dr. Balmis General University Hospital, 03010 Alicante, Spain. LA - eng PT - Journal Article DEP - 20231020 PL - Switzerland TA - Pharmaceuticals (Basel) JT - Pharmaceuticals (Basel, Switzerland) JID - 101238453 PMC - PMC10610471 OTO - NOTNLM OT - adverse events OT - autism spectrum disorder OT - dopaminergic system OT - pharmacogenetics OT - polypharmacy COIS- The authors declare no conflict of interest. EDAT- 2023/10/28 11:44 MHDA- 2023/10/28 11:45 PMCR- 2023/10/20 CRDT- 2023/10/28 01:24 PHST- 2023/08/25 00:00 [received] PHST- 2023/10/15 00:00 [revised] PHST- 2023/10/17 00:00 [accepted] PHST- 2023/10/28 11:45 [medline] PHST- 2023/10/28 11:44 [pubmed] PHST- 2023/10/28 01:24 [entrez] PHST- 2023/10/20 00:00 [pmc-release] AID - ph16101496 [pii] AID - pharmaceuticals-16-01496 [pii] AID - 10.3390/ph16101496 [doi] PST - epublish SO - Pharmaceuticals (Basel). 2023 Oct 20;16(10):1496. doi: 10.3390/ph16101496.